US Pharma MarketingAngitia ends Phase 3 in disc disease; Abivax raises $800M on colitis data
Angitia halts a Phase 3 disc-disease trial, Abivax prices an upsized $800M offering, and AlzeCure lands a $2.2B NeuroRestore deal with QuantumCell. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
🩻 Angitia Biopharmaceuticals drops Phase 3: The US and China biotech terminated a late-stage trial of AGA111 in patients with degenerative disc disease who had a lumbar interbody fusion, according to an
Source: Endpoints News